Telix的第三阶段ZIRCON试验显示,在美国规定的批准程序中,TLX250-CDx对肾癌进行了高度精确的检测。 Telix's Phase III ZIRCON trial showed high-accuracy detection of kidney cancer with TLX250-CDx in US-bound approval process.

Telix制药公司宣布其在"柳叶刀瘤学"杂志上发表的ZIRCON III期试验的有希望的结果. Telix Pharmaceuticals announced promising results from its Phase III ZIRCON trial, published in The Lancet Oncology. 在未确定质的患者中,研究中的PET剂TLX250- CDx (Zircaix®) 检测清细胞细胞癌 (ccRCC) 的准确度高,达到86%的灵敏度和87%的特异性. The investigational PET agent TLX250-CDx (Zircaix®) demonstrated high accuracy in detecting clear cell renal cell carcinoma (ccRCC) in patients with indeterminate renal masses, achieving 86% sensitivity and 87% specificity. 如果获得FDA批准, 这将是美国首个针对癌的PET药物. If approved by the FDA, it would be the first targeted PET agent for kidney cancer available in the U.S.